Methoxsalen-d3

Methoxsalen-d3 is the deuterium labeled Methoxsalen[1]. Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight[2].

Product Specifications

CAS Number

[80386-99-8]

Product Name Alternative

8-Methoxypsoralen-d3; Xanthotoxin-d3; 8-MOP-d3

UNSPSC

12352005

Hazard Statement

H302, H317, H341, H351

Target

Cytochrome P450

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Inflammation/Immunology

Purity

99.93

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])OC1=C(OC=C2)C2=CC(C=C3)=C1OC3=O

Molecular Formula

C12H5D3O4

Molecular Weight

219.21

Precautions

H302, H317, H341, H351

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Alsharari SD, et al. Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. Nicotine Tob Res. 2014 Jan;16 (1) :18-25.